Back to Webinars

Uncovering the Complete Picture: Transforming Rare Disease Care for Every Patient

Wednesday, November 18, 2026
10:00 am PDT
1 hour

Diagnostic odysseys in rare disease often leave critical gaps in care. When standard approaches fall short, comprehensive genomic insight is essential to illuminating those blind spots. Join Dr. TJ Slavin, Chief Medical Officer, to explore how Ambry is setting a new bar for clinical whole genome sequencing, delivering unprecedented clarity, maximizing diagnostic yield, and driving equitable care across diverse patient populations.

In this session, you’ll discover how Ambry helps clinicians get the most out of every genome through:

-Broader Variant Calling: Capturing complex structural variants, intronic changes, and non-coding regions.
-Pangenome Graphical Mapping: Leveraging global genomic diversity to reduce reference bias and improve diagnostic accuracy for underrepresented populations.
-Functional Precision with RNA: Utilizing GenomeReveal™️ to clarify splicing impacts and convert VUSs into definitive answers.
-Continuous Care with Patient for Life™️: A first-of-its-kind, lab-driven reanalysis program that automatically updates patient reports as new gene-disease associations are discovered, ensuring genomic data continues to deliver lifelong clinical value so no rare disease patient is left behind.

*CEU credit is not available for this webinar.*

TJ Slavin Headshot 600×600
TJ Slavin
MD | Presenter
Dr. Slavin is a physician-scientist and biotech executive, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. He is the Chief Medical Officer of Diagnostics at Tempus. He previously held the positions of Chief Clinical Officer of Molecular Oncology at Quest Diagnostics and Chief Medical Officer at Myriad Genetics. He was a former assistant professor in the departments of Medical Oncology and Population Sciences at City of Hope National Medical Center. Dr. Slavin graduated medical school with Alpha Omega-Alpha-honors from the University of South Florida. He completed his residency programs at Case Western Reserve in Cleveland, Ohio; this training included a postdoctoral research year in genetic epidemiology. He has also completed graduate coursework toward a Master’s degree in clinical research through the University of Southern California and holds a Master’s in Business Administration through Columbia Southern University. He is a Touch4Life board member, a breast cancer awareness nonprofit for women of color. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the Collaborative Group of the Americas on Inherited Colorectal Cancer, and is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer. He has served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin is an active faculty member of City of Hope’s hereditary genomics training program. He is a well-respected researcher in the field of medical genetics, publishing over 85 journal articles collectively evaluating genomic data from over 500,000 patients, multiple book chapters, and providing numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants, and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.